Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
July 10, 2020

Insilico and Arctoris partner on Covid-19 AI

By Chloe Kent

Drug discovery biotech Insilico Medicine has announced a partnership with automated drug discovery platform Arctoris, using artificial intelligence (AI) to identify potential Covid-19 treatments.

They have utilised their technologies to discover, synthesise and profile a set of inhibitors for Covid-19 treatment. Insilico identified novel small molecules using its AI capabilities, with Arctoris rapidly evaluating the intended biological actions on its robotic platform. This has enabled them to profile a set of potent inhibitors that can help patients by modulating the life-threatening cytokine storm caused by Covid-19.

Arctoris co-founder and CEO Martin-Immanuel Bittner said: “During the Covid-19 pandemic, time is of the essence, and this project demonstrates that together, we are able to accelerate the drug discovery process, and create and progress new drug candidates faster and cheaper.”

Related Companies

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU